VIR News and Press, Vir Biotechnology Inc. From 03/06/23

2023-03-06 07:47:59 ET Vir Biotechnology ( NASDAQ: VIR ) added ~5% pre-market Monday after JPMorgan upgraded the COVID-19 drugmaker citing upcoming data readouts for VIR-2482 and VIR-2218, candidates targeted at influenza A and Hepatitis B Virus, respectively. In mid-202...

2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43 rd Annual Health Care Confer...

Palm Beach, FL – February 28, 2023 – FinancialNewsMedia.com News Commentary –  The Coronavirus Global Market has been growing in the past few years and is anticipated to continue to grow in the next several years. In fact, the whole vaccines market is project...

Vir Therapeutics ( NASDAQ: VIR ) is down 5% in after-hours trading after its Q4 2022 financial results missed on the top and bottom lines . Year over year, revenue declined ~94% due to collaboration revenue going to ~$21.6M from ~$809.5M. Vir ( VIR ) swung to a net los...

Vir Biotechnology press release ( NASDAQ: VIR ): Q4 GAAP EPS of -$0.76 misses by $0.42 . Revenue of $49.4M (-93.9% Y/Y) misses by $84.84M . For further details see: Vir Biotechnology GAAP EPS of -$0.76 misses by $0.42, revenue of $49.4M misses by $84.84M

– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of sotrovimab collaboration revenue recognized in 2022 – ...

SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending the use of sotrovimab, an investigational SARS-CoV-2 neutralizin...

Vir Biotechnology Inc ( NASDAQ: VIR ) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company. Vir stock has upside to $53 a share On Tuesday, Paul Choi upgraded the biotech stock to “buy” and raised ...

Vir Biotechnology ( NASDAQ: VIR ) gained ~9% on Tuesday after Goldman Sachs upgraded the COVID-19 treatment maker to Buy from Hold, citing a post-pandemic leg to its story given its experimental flu vaccine. The upgrade comes as Vir ( VIR ) prepares to report initial data for ...